Recent Advances in the Management of Adverse Events Associated with Lorlatinib
Open Access
- 1 September 2023
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 731-738
Abstract
As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.Keywords
This publication has 40 references indexed in Scilit:
- Lorlatinib: First Global ApprovalDrugs, 2019
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyThe Lancet Oncology, 2018
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerCancer Discovery, 2018
- The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)Molecular Cancer, 2018
- MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancerMolecular Cancer, 2018
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialThe Lancet Oncology, 2017
- Non-small cell lung cancer: current treatment and future advancesTranslational Lung Cancer Research, 2016
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsJournal of Medicinal Chemistry, 2014
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2013
- Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClinical Pharmacology & Therapeutics, 2006